MISSION HOSPITAL INC
- Type
- Teaching hospital
- Where
- ASHEVILLE, NC
- Medicare CCN
- 340002
- Received
- $1,068,820 in 258 records, 2019 ($18,714 general, $1,050,106 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: MISSION HOSPITAL Fuzzy (name and state)
- Federal award recipient: MISSION HOSPITAL, INC. Fuzzy (name and state)
- Trademark owner: MISSION HOSPITAL, INC. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 15 | $18,714 |
| 2019 | Research payment | 243 | $1,050,106 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Abbott Laboratories | 41 | $427,769 | 2019 |
| Allergan, Inc. | 10 | $161,140 | 2019 |
| Amgen Inc. | 11 | $83,072 | 2019 |
| TESARO, Inc. | 11 | $77,712 | 2019 |
| Merck Sharp & Dohme LLC | 11 | $70,450 | 2019 |
| Medtronic Vascular, Inc. | 38 | $56,186 | 2019 |
| AstraZeneca Pharmaceuticals LP | 5 | $40,667 | 2019 |
| United Therapeutics Corporation | 12 | $26,610 | 2019 |
| Boston Scientific Corporation | 22 | $21,402 | 2019 |
| W. L. Gore & Associates, Inc. | 7 | $18,870 | 2019 |
| Eisai Inc. | 11 | $18,573 | 2019 |
| Zimmer Biomet Holdings, Inc. | 3 | $9,808 | 2019 |
| AtriCure, Inc. | 1 | $9,000 | 2019 |
| Surmodics, Inc. | 9 | $8,870 | 2019 |
| Stryker Corporation | 6 | $8,435 | 2019 |
| American Regent | 4 | $8,152 | 2019 |
| GE HEALTHCARE | 1 | $6,000 | 2019 |
| Endologix LLC | 1 | $5,460 | 2019 |
| BIOTRONIK INC. | 37 | $4,414 | 2019 |
| Tandem Diabetes Care, Inc. | 10 | $2,800 | 2019 |
| Eli Lilly and Company | 2 | $1,401 | 2019 |
| Bolton Medical Inc | 2 | $1,000 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 2 | $523 | 2019 |
| ABBVIE INC. | 1 | $500 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 243 | $1,050,106 |
| Gift | 3 | $9,808 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 12 | $8,905 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $6,714 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $3,058 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $182 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $36 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-26 | United Therapeutics Corporation | $330 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-12-23 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M12-914 | 2019 | |
| 2019-12-21 | Amgen Inc. | $800 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-12-18 | GE HEALTHCARE | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Device, DETECTION & GUIDANCE SOLUTIONS | 2019 | |
| 2019-12-16 | Eisai Inc. | $1,968 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-12-16 | Eisai Inc. | $1,615 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-12-16 | Medtronic Vascular, Inc. | $1,169 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $188 | Research payment | Cash or cash equivalent | General Brady Device, Brady | APPRAISE ATP | 2019 |
| 2019-12-13 | Abbott Laboratories | $8,250 | Research payment | Cash or cash equivalent | Optical Coherence Tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2019 |
| 2019-12-13 | Abbott Laboratories | $2,500 | Research payment | Cash or cash equivalent | Optical Coherence Tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2019 |
| 2019-12-13 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Optical Coherence Tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2019 |
| 2019-12-13 | W. L. Gore & Associates, Inc. | $128 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $3,080 | Research payment | Cash or cash equivalent | General Brady Device, Brady | APPRAISE ATP | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | General Brady Device, Brady | APPRAISE ATP | 2019 |
| 2019-11-22 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Durata Leads Device, Cardiac Arrhythmias and Heart Failure | SJM Cardiac Lead Assessment Study | 2019 |
| 2019-11-21 | Eisai Inc. | $1,615 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-11-21 | Eisai Inc. | $1,615 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-11-13 | Abbott Laboratories | $7,512 | Research payment | Cash or cash equivalent | Tendyne Mitral Valve System Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2019 |
| 2019-11-11 | Medtronic Vascular, Inc. | $2,790 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-11-07 | Stryker Corporation | $1,336 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM KNEE OUTCOMES STUDY | 2019 |
| 2019-11-06 | Abbott Laboratories | $6,174 | Research payment | Cash or cash equivalent | Portico Resheathable Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Continued Access Protocol | 2019 |
| 2019-11-06 | Surmodics, Inc. | $1,464 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-11-06 | Surmodics, Inc. | $1,464 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-11-05 | Eisai Inc. | $1,615 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-10-30 | Surmodics, Inc. | $750 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-10-30 | Surmodics, Inc. | $500 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-10-30 | Bolton Medical Inc | $250 | Research payment | Cash or cash equivalent | Treovance Phase II Trial Device | Treovance Phase II Trial | 2019 |
| 2019-10-24 | TESARO, Inc. | $10,908 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-10-16 | Abbott Laboratories | $7,106 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-10-15 | Allergan, Inc. | $14,517 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-10-09 | American Regent | $375 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-10-08 | Amgen Inc. | $296 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-10-07 | Medtronic Vascular, Inc. | $500 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-10-03 | Endologix LLC | $5,460 | Research payment | Cash or cash equivalent | Ovation Device, Cardiology/Vascular Diseases | ELEVATE IDE | 2019 |
| 2019-10-03 | Stryker Corporation | $750 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM KNEE OUTCOMES STUDY | 2019 |
| 2019-10-02 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-01 | Allergan, Inc. | $34,001 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-10-01 | Eisai Inc. | $1,666 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-10-01 | Eisai Inc. | $1,373 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-10-01 | Eisai Inc. | $952 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-09-30 | TESARO, Inc. | $4,093 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-09-26 | Abbott Laboratories | $1,541 | Research payment | Cash or cash equivalent | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2019 |
| 2019-09-26 | Abbott Laboratories | $640 | Research payment | Cash or cash equivalent | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2019 |
| 2019-09-26 | Abbott Laboratories | $384 | Research payment | Cash or cash equivalent | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2019 |
| 2019-09-24 | Allergan, Inc. | $28,880 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-09-18 | Medtronic Vascular, Inc. | $1,024 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-09-17 | Medtronic Vascular, Inc. | $1,725 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-09-16 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | General Brady Device, Brady | APPRAISE ATP | 2019 |
| 2019-09-16 | Boston Scientific Corporation | $604 | Research payment | Cash or cash equivalent | General Brady Device, Brady | APPRAISE ATP | 2019 |
| 2019-09-13 | W. L. Gore & Associates, Inc. | $11,404 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Gore Research and Development | 2019 |
| 2019-09-13 | W. L. Gore & Associates, Inc. | $456 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-09-12 | Boston Scientific Corporation | $175 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-09-09 | Medtronic Vascular, Inc. | $1,250 | Research payment | Cash or cash equivalent | Attain Stability Quad | 2019 | |
| 2019-09-09 | Medtronic Vascular, Inc. | $1,200 | Research payment | Cash or cash equivalent | Attain Stability Quad | 2019 | |
| 2019-09-05 | AtriCure, Inc. | $9,000 | Research payment | Cash or cash equivalent | ATRICURE SYNERGY ABLATION SYSTEMS Device, CARDIOVASCULAR | ATRICURE CRYOICE LESIONS FOR PERSISTENT AND LONGSTANDING PERSISTENT ATRIAL FIBRILLATION TREATMENT DURING CONCOMITANT ON- | 2019 |
| 2019-09-05 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-09-04 | Allergan, Inc. | $28,880 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-09-03 | Boston Scientific Corporation | $403 | Research payment | Cash or cash equivalent | EMBLEM Device, TACHY | UNTOUCHED | 2019 |
| 2019-08-28 | Surmodics, Inc. | $750 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-08-28 | Surmodics, Inc. | $500 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-08-26 | Eisai Inc. | $3,537 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-08-26 | Eisai Inc. | $1,482 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-08-26 | Eisai Inc. | $1,131 | Research payment | Cash or cash equivalent | Lenvima Drug, Oncology | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2019 |
| 2019-08-22 | Stryker Corporation | $300 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM KNEE OUTCOMES STUDY | 2019 |
| 2019-08-21 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-15 | Abbott Laboratories | $731 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-08-15 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-14 | United Therapeutics Corporation | $12,507 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-08-14 | Stryker Corporation | $2,338 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM KNEE OUTCOMES STUDY | 2019 |
| 2019-08-14 | United Therapeutics Corporation | $375 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAIL | 2019 |
| 2019-08-08 | Medtronic Vascular, Inc. | $5,261 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-08-07 | Abbott Laboratories | $14,716 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-08-07 | Abbott Laboratories | $9,538 | Research payment | Cash or cash equivalent | Tendyne Mitral Valve System Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2019 |
| 2019-08-07 | Medtronic Vascular, Inc. | $1,280 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-08-06 | Allergan, Inc. | $26,343 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-08-06 | Allergan, Inc. | $10,000 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-08-06 | Allergan, Inc. | $3,000 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-08-06 | Allergan, Inc. | $2,000 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-08-05 | Medtronic Vascular, Inc. | $1,296 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-08-02 | E.R. Squibb & Sons, L.L.C. | $500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer W | 2019 |
| 2019-07-31 | Abbott Laboratories | $58,074 | Research payment | Cash or cash equivalent | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2019 |
| 2019-07-31 | Abbott Laboratories | $9,599 | Research payment | Cash or cash equivalent | Portico Resheathable Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Continued Access Protocol | 2019 |
| 2019-07-31 | Abbott Laboratories | $1,889 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-07-30 | Allergan, Inc. | $750 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-07-30 | Abbott Laboratories | $105 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-25 | Eli Lilly and Company | $351 | Research payment | In-kind items and services | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2019 | |
| 2019-07-24 | United Therapeutics Corporation | $4,088 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-07-24 | Abbott Laboratories | $976 | Research payment | Cash or cash equivalent | Durata Leads Device, Cardiac Arrhythmias and Heart Failure | SJM Cardiac Lead Assessment Study | 2019 |
| 2019-07-24 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-17 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-17 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-17 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-17 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-16 | TESARO, Inc. | $3,029 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-07-16 | TESARO, Inc. | $608 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-07-16 | TESARO, Inc. | $416 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-07-11 | Allergan, Inc. | $12,768 | Research payment | Cash or cash equivalent | A MULTI-CENTERED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY O | 2019 | |
| 2019-07-10 | United Therapeutics Corporation | $3,503 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-07-08 | American Regent | $3,701 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-07-05 | Medtronic Vascular, Inc. | $2,319 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP AF First | 2019 |
| 2019-07-05 | E.R. Squibb & Sons, L.L.C. | $23 | Research payment | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K A | 2019 |
| 2019-07-02 | Medtronic Vascular, Inc. | $370 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-07-01 | Boston Scientific Corporation | $807 | Research payment | Cash or cash equivalent | EMBLEM Device, TACHY | UNTOUCHED | 2019 |
| 2019-06-28 | W. L. Gore & Associates, Inc. | $2,278 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-06-28 | W. L. Gore & Associates, Inc. | $750 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-06-26 | Merck Sharp & Dohme LLC | $11,400 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-06-26 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-06-24 | Medtronic Vascular, Inc. | $370 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-06-20 | Abbott Laboratories | $984 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-06-19 | Medtronic Vascular, Inc. | $552 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $5,793 | Research payment | Cash or cash equivalent | General Brady Device, Brady | APPRAISE ATP | 2019 |
| 2019-06-12 | United Therapeutics Corporation | $926 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-06-12 | United Therapeutics Corporation | $926 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAIL | 2019 |
| 2019-06-11 | TESARO, Inc. | $26,187 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $300 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $300 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $207 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $166 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $166 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $32 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $9 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $9 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $9 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $9 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $9 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-11 | BIOTRONIK INC. | $9 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-06-07 | Bolton Medical Inc | $750 | Research payment | Cash or cash equivalent | Treovance Phase II Trial Device | Treovance Phase II Trial | 2019 |
| 2019-06-06 | Medtronic Vascular, Inc. | $266 | Research payment | Cash or cash equivalent | Attain Stability Quad | 2019 | |
| 2019-06-05 | Medtronic Vascular, Inc. | $3,288 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-06-03 | Boston Scientific Corporation | $570 | Research payment | Cash or cash equivalent | EMBLEM Device, TACHY | UNTOUCHED | 2019 |
| 2019-06-03 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-05-30 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-05-23 | Surmodics, Inc. | $1,010 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-21 | Stryker Corporation | $1,604 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM KNEE OUTCOMES STUDY | 2019 |
| 2019-05-16 | Abbott Laboratories | $10,000 | Research payment | Cash or cash equivalent | Tendyne Mitral Valve System Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2019 |
| 2019-05-16 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Tendyne Mitral Valve System Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2019 |
| 2019-05-14 | TESARO, Inc. | $722 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-05-14 | Medtronic Vascular, Inc. | $370 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-05-09 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-05-09 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-05-09 | Medtronic Vascular, Inc. | $82 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-05-08 | Abbott Laboratories | $87,396 | Research payment | Cash or cash equivalent | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2019 |
| 2019-05-08 | Abbott Laboratories | $7,806 | Research payment | Cash or cash equivalent | Portico Resheathable Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Continued Access Protocol | 2019 |
| 2019-05-08 | Abbott Laboratories | $652 | Research payment | Cash or cash equivalent | Durata Leads Device, Cardiac Arrhythmias and Heart Failure | SJM Cardiac Lead Assessment Study | 2019 |
| 2019-05-06 | Eli Lilly and Company | $1,050 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2019 | |
| 2019-05-06 | Boston Scientific Corporation | $149 | Research payment | Cash or cash equivalent | EMBLEM Device, TACHY | UNTOUCHED | 2019 |
| 2019-05-03 | Amgen Inc. | $9,347 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-05-02 | Amgen Inc. | $58,200 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-05-02 | Surmodics, Inc. | $1,010 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-02 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-05-02 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-05-01 | Abbott Laboratories | $650 | Research payment | Cash or cash equivalent | TrifectaGT Device, Cardiac Arrhythmias and Heart Failure | Trifecta GT Post Market Clinical Follow-up | 2019 |
| 2019-04-25 | Medtronic Vascular, Inc. | $554 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-04-25 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | TrifectaGT Device, Cardiac Arrhythmias and Heart Failure | Trifecta GT Post Market Clinical Follow-up | 2019 |
| 2019-04-25 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | TrifectaGT Device, Cardiac Arrhythmias and Heart Failure | Trifecta GT Post Market Clinical Follow-up | 2019 |
| 2019-04-25 | Medtronic Vascular, Inc. | $450 | Research payment | Cash or cash equivalent | Aptus Heli-FX Device, Aortic EndoAnchors | ANCHOR Registry | 2019 |
| 2019-04-24 | Abbott Laboratories | $22,979 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-04-24 | United Therapeutics Corporation | $154 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-04-23 | Medtronic Vascular, Inc. | $1,929 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-04-18 | Boston Scientific Corporation | $435 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-04-17 | Abbott Laboratories | $12,595 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-04-17 | Amgen Inc. | $3,715 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-04-17 | Medtronic Vascular, Inc. | $50 | Research payment | Cash or cash equivalent | Aptus Heli-FX Device, Aortic EndoAnchors | ANCHOR Registry | 2019 |
| 2019-04-16 | BIOTRONIK INC. | $500 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2019 |
| 2019-04-12 | W. L. Gore & Associates, Inc. | $2,944 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-04-10 | American Regent | $2,050 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-04-10 | United Therapeutics Corporation | $676 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAIL | 2019 |
| 2019-04-10 | United Therapeutics Corporation | $676 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-04-08 | Amgen Inc. | $606 | Research payment | In-kind items and services | GALACTIC-HF | 2019 | |
| 2019-04-02 | Merck Sharp & Dohme LLC | $4,700 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-04-01 | Boston Scientific Corporation | $254 | Research payment | Cash or cash equivalent | EMBLEM Device, TACHY | UNTOUCHED | 2019 |
| 2019-03-31 | Abbott Laboratories | $220 | Research payment | In-kind items and services | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico IDE | 2019 |
| 2019-03-29 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-03-29 | Merck Sharp & Dohme LLC | $2,000 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-03-29 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-03-29 | Merck Sharp & Dohme LLC | $250 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-03-28 | Amgen Inc. | $3,066 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-03-27 | Amgen Inc. | $3,600 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-03-26 | Medtronic Vascular, Inc. | $360 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-03-22 | Medtronic Vascular, Inc. | $2,000 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP AF First | 2019 |
| 2019-03-20 | Abbott Laboratories | $51,418 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-03-19 | Medtronic Vascular, Inc. | $1,250 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-03-19 | TESARO, Inc. | $750 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
| 2019-03-19 | Boston Scientific Corporation | $500 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $381 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-03-15 | W. L. Gore & Associates, Inc. | $908 | Research payment | Cash or cash equivalent | Conformable TAG Thoracic Endoprosthesis Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-03-14 | Medtronic Vascular, Inc. | $4,373 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-03-12 | Boston Scientific Corporation | $435 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-03-07 | Medtronic Vascular, Inc. | $554 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP Persistent AF | 2019 |
| 2019-02-27 | United Therapeutics Corporation | $1,224 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAIL | 2019 |
| 2019-02-27 | United Therapeutics Corporation | $1,224 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-02-26 | Medtronic Vascular, Inc. | $768 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-02-26 | TESARO, Inc. | $750 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F | 2019 |
The latest 200 records of 258.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Asheville, NC, county Buncombe County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Asheville, NC | County Buncombe County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 94,535 | 274,360 | 10,730,404 |
| Population, 2020 census P1 | 94,589 | 269,452 | 10,439,388 |
| Median age B01002 | 40.7 | 42.6 | 39.1 |
| Under 18 B01001 | 14.8% | 17.8% | 21.8% |
| 65 and over B01001 | 20.1% | 21.2% | 17.2% |
| Households B11001 | 37,394 | 101,855 | 4,282,345 |
| Foreign born B05002 | 7.0% | 6.7% | 9.1% |
| Median household income B19013 | $71,102 | $74,436 | $72,388 |
| Median family income B19113 | $98,384 | $95,650 | $90,290 |
| Per capita income B19301 | $45,430 | $43,371 | $41,385 |
| Poverty rate B17001 | 14.3% | 11.8% | 13.0% |
| Unemployment rate B23025 | 5.1% | 4.3% | 4.7% |
| Civilian labor force B23025 | 50,778 | 136,517 | 5,336,863 |
| Mean commute (minutes) B08013 | 18.2 | 21.1 | 25.1 |
| Bachelor's degree or higher B15003 | 53.4% | 45.9% | 35.7% |
| Housing units B25001 | 50,034 | 134,483 | 4,895,668 |
| Owner-occupied B25003 | 51.9% | 66.2% | 66.6% |
| Renters B25003 | 48.1% | 33.8% | 33.4% |
| Median home value B25077 | $440,000 | $391,800 | $288,900 |
| Median gross rent B25064 | $1,402 | $1,362 | $1,228 |
| White, not Hispanic B03002 | 79.8% | 80.8% | 60.0% |
| Black B03002 | 8.1% | 4.8% | 20.0% |
| Hispanic or Latino B03002 | 6.6% | 8.6% | 11.3% |
| Asian B03002 | 1.1% | 1.1% | 3.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Asheville, NC.
Comments